![](https://endpts.com/wp-content/uploads/2022/02/David-Meek-Mirati-Getty-tile-scaled.jpg)
David Meek, Mirati Therapeutics CEO (Photographer: Marlene Awaad/Bloomberg via Getty Images)
#ESMO22: Mirati vs. Amgen: Scrappy KRAS G12C contender outperforms its giant rival in colorectal cancer
PARIS — This weekend at ESMO, the KRAS battle between Amgen and its pesky biotech rivals at Mirati will continue with new slices of combo data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.